Eton Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent
Eton Pharmaceuticals, Inc. (ETON) reported Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent of 0.00% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent · last filed 2024-03-14
- Eton Pharmaceuticals, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2023 was 0.00%.
- Eton Pharmaceuticals, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2022 was 0.00%.
- Eton Pharmaceuticals, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2021 was 0.00%.
- Eton Pharmaceuticals, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2020 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent 8 month | Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent 12 month |
|---|---|---|
| 2023-12-31 | 0.00% 10-K · filed 2024-03-14 | |
| 2022-12-31 | 0.00% 10-K · filed 2024-03-14 | |
| 2021-12-31 | 0.00% 10-K · filed 2024-03-14 | |
| 2020-12-31 | 0.00% 10-K · filed 2021-03-16 | |
| 2019-12-31 | 0.00% 10-K · filed 2021-03-16 | |
| 2018-12-31 | 0.00% 10-K · filed 2019-03-25 | 0.00% 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |